Carvalho Henriques Beatriz, Yang Esther H, Lapetina Diego, Carr Michael S, Yavorskyy Vasyl, Hague Joshua, Aitchison Katherine J
Department of Psychiatry, University of Alberta, Edmonton, AB, Canada.
Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada.
Front Genet. 2020 Dec 8;11:491895. doi: 10.3389/fgene.2020.491895. eCollection 2020.
Many genetic variants in drug metabolizing enzymes and transporters have been shown to be relevant for treating psychiatric disorders. Associations are strong enough to feature on drug labels and for prescribing guidelines based on such data. A range of commercial tests are available; however, there is variability in included genetic variants, methodology, and interpretation. We herein provide relevant background for understanding clinical associations with specific variants, other factors that are relevant to consider when interpreting such data (such as age, gender, drug-drug interactions), and summarize the data relevant to clinical utility of pharmacogenetic testing in psychiatry and the available prescribing guidelines. We also highlight areas for future research focus in this field.
药物代谢酶和转运蛋白中的许多基因变异已被证明与精神疾病的治疗相关。这些关联足够强，足以在药物标签上体现，并用于基于此类数据的处方指南。有一系列商业检测可供使用；然而，所包含的基因变异、方法和解读存在差异。我们在此提供相关背景知识，以帮助理解与特定变异的临床关联、解读此类数据时需要考虑的其他相关因素（如年龄、性别、药物相互作用），并总结与精神科药物遗传学检测临床效用相关的数据以及现有的处方指南。我们还强调了该领域未来研究的重点方向。
